GlassScriptPhysician profile
Jonathan A Freeman
NPI 1184701559
$4,345.01
in general payments reported to CMS, 2019-2025
21 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $176 · 2021: $209 · 2022: $1,700 · 2023: $339 · 2024: $1,031 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059 · Travel and Lodging: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.24 |
| Travel and Lodging | $528.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,313.14 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $982.17 | 2022 | |
| Amgen INC. | $367.06 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $299.54 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $280.21 | 2019-2024 | |
| Edwards Lifesciences Corporation | $251.65 | 2024 | Pascal |
| Pfizer INC. | $160.89 | 2019-2024 | |
| Boston Scientific Corporation | $97.23 | 2019-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $95.13 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $87.87 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.18 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $77.05 | 2022-2025 | Verquvo, Capvaxive |
| Kiniksa Pharmaceuticals International, Plc | $76.48 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $38.27 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.28 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.81 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $21.52 | 2025 | Evkeeza |
| Atricure, INC. | $21.28 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.88 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $14.91 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $12.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.